← Leaderboards
Tomasz Skorski
Temple Univ Of The Commonwealth
$21,974,892
Attributed
$25,756,494
Total exposure
14
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,756,494 · 14
By mechanism
R01$24,940,158 · 11
R21$736,230 · 2
R29$80,106 · 1
Top collaborators
- Alexander V Mazin5 shared
- Richard T Pomerantz5 shared
- David L Wiest3 shared
Others in their field
Top investigators on “Dna Repair”
- John A Tainer · Scripps Research Institute$45,990,082
- Aziz Sancar · University Of North Carolina Chapel Hill$30,640,499
- Patrick Sung · University Of Texas Hlth Sci Ctr San Ant$30,442,761
- John M Essigmann · Massachusetts Institute Of Technology$27,654,594
- Loic Le Marchand · University Of Hawaii At Manoa$26,643,180
- Maria Jasin · Sloan-Kettering Institute For Cancer Res$25,953,946
Research focus
Dna RepairCellsMediatingLeukemiaMutationReportingPathway InteractionsModalityPlayResponseMutantGeneticResistanceRepairedProtein Tyrosine KinaseHomologous RecombinationDouble Strand Break RepairDna Double Strand BreakStem CellsPreventTherapeutic EffectIn VitroCancer CellOncogenic
Grant awards (64)
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms$707,044
R01 · FY2025 · CA
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms$671,691
R01 · FY2024 · CA
AML mutation-guided drugging of DNA repair$523,054
R01 · FY2024 · CA · contact PI
PolQ as a novel therapeutic target in AML$499,929
R01 · FY2024 · CA · contact PI
MPN-inducing mutations as biomarkers of synthetic lethality$406,919
R01 · FY2024 · CA · contact PI
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors$387,339
R01 · FY2024 · CA · contact PI
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL$377,631
R01 · FY2024 · CA · contact PI
Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms$707,046
R01 · FY2023 · CA
AML mutation-guided drugging of DNA repair$549,888
R01 · FY2023 · CA · contact PI
PolQ as a novel therapeutic target in AML$523,880
R01 · FY2023 · CA · contact PI
MPN-inducing mutations as biomarkers of synthetic lethality$419,768
R01 · FY2023 · CA · contact PI
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors$399,571
R01 · FY2023 · CA · contact PI
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL$389,557
R01 · FY2023 · CA · contact PI
AML mutation-guided drugging of DNA repair$553,754
R01 · FY2022 · CA · contact PI
PolQ as a novel therapeutic target in AML$535,835
R01 · FY2022 · CA · contact PI
MPN-inducing mutations as biomarkers of synthetic lethality$419,768
R01 · FY2022 · CA · contact PI
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors$399,569
R01 · FY2022 · CA · contact PI
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL$388,003
R01 · FY2022 · CA · contact PI
AML mutation-guided drugging of DNA repair$574,264
R01 · FY2021 · CA · contact PI
PolQ as a novel therapeutic target in AML$556,097
R01 · FY2021 · CA · contact PI
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia$486,669
R01 · FY2021 · CA · contact PI
MPN-inducing mutations as biomarkers of synthetic lethality$427,660
R01 · FY2021 · CA · contact PI
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL$387,997
R01 · FY2021 · CA · contact PI
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors$376,152
R01 · FY2021 · CA · contact PI
AML mutation-guided drugging of DNA repair$595,466
R01 · FY2020 · CA · contact PI
PolQ as a novel therapeutic target in AML$565,257
R01 · FY2020 · CA · contact PI
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia$486,669
R01 · FY2020 · CA · contact PI
MPN-inducing mutations as biomarkers of synthetic lethality$427,660
R01 · FY2020 · CA · contact PI
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL$380,072
R01 · FY2020 · CA · contact PI
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors$376,152
R01 · FY2020 · CA · contact PI
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia$470,806
R01 · FY2019 · CA · contact PI
Targeting DNA repair to eradicate TKI-refractory/resistant CML$490,024
R01 · FY2018 · CA · contact PI
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia$485,369
R01 · FY2018 · CA · contact PI
Targeting DNA repair to eradicate TKI-refractory/resistant CML$504,699
R01 · FY2017 · CA · contact PI
Normal ABL1 kinase as tumor suppressor and therapeutic target in leukemia$485,369
R01 · FY2017 · CA · contact PI
Targeting DNA repair to eradicate TKI-refractory/resistant CML$531,250
R01 · FY2016 · CA · contact PI
Personalized RAD52-dependent synthetic lethality to eliminate T-ALL$169,650
R21 · FY2016 · CA · contact PI
Targeting DNA repair to eradicate TKI-refractory/resistant CML$531,250
R01 · FY2015 · CA · contact PI
Personalized RAD52-dependent synthetic lethality to eliminate T-ALL$203,580
R21 · FY2015 · CA · contact PI
Targeting DNA repair to eradicate TKI-refractory/resistant CML$537,724
R01 · FY2014 · CA · contact PI
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."$298,713
R01 · FY2014 · CA · contact PI
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."$289,474
R01 · FY2013 · CA · contact PI
Genomic instability causes imatinib resistance in CML$400,685
R01 · FY2012 · CA · contact PI
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."$307,951
R01 · FY2012 · CA · contact PI
Genomic instability causes imatinib resistance in CML$400,683
R01 · FY2011 · CA · contact PI
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."$307,951
R01 · FY2011 · CA · contact PI
Genomic instability causes imatinib resistance in CML$413,076
R01 · FY2010 · CA · contact PI
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."$315,400
R01 · FY2010 · CA · contact PI
Genome instability in leukemia stem cell$198,000
R21 · FY2010 · CA · contact PI
Genomic instability causes imatinib resistance in CML$404,972
R01 · FY2009 · CA · contact PI
Genome instability in leukemia stem cell$165,000
R21 · FY2009 · CA · contact PI
Genomic instability causes imatinib resistance in CML$98,325
R01 · FY2009 · CA · contact PI
Genomic instability causes imatinib resistance in CML$329,781
R01 · FY2008 · CA · contact PI
Role of STATs in BCR/ABL induced leukemias$281,059
R01 · FY2005 · CA
PI 3K PATHWAY IN BCR/ABL INDUCED LEUKEMIAS$283,950
R01 · FY2004 · CA
Role of STATs in BCR/ABL induced leukemias$281,059
R01 · FY2004 · CA
PI 3K PATHWAY IN BCR/ABL INDUCED LEUKEMIAS$283,950
R01 · FY2003 · CA
Role of STATs in BCR/ABL induced leukemias$281,059
R01 · FY2003 · CA
PI 3K PATHWAY IN BCR/ABL INDUCED LEUKEMIAS$283,950
R01 · FY2002 · CA
Role of STATs in BCR/ABL induced leukemias$281,059
R01 · FY2002 · CA
PI 3K PATHWAY IN BCR/ABL INDUCED LEUKEMIAS$283,950
R01 · FY2001 · CA
Role of STATs in BCR/ABL induced leukemias$281,059
R01 · FY2001 · CA
PI 3K PATHWAY IN BCR/ABL INDUCED LEUKEMIAS$295,200
R01 · FY2000 · CA
PI-3K IN BCR/ABL TYROSINE KINASE-INDUCED LEUKEMIAS$80,106
R29 · FY2000 · CA